• Stockholm3 – the future of prostate cancer diagnostics

  • New analysis in European Urology finds Stockholm3 cost effective for population-based screening

Want to take Stockholm3?

Prostate cancer is the second most common cancer in the world, 1.4 million men are diagnosed yearly. Early detection is the key to successful treatment. Currently, a number of caregivers offer Stockholm3.

  • 75000

    Participants in clinical studies

  • 100 %

    More cases of aggressive cancers found

  • 50 %

    Fewer unnecessary biopsies

  • 17-28 %

    Reduced healthcare costs

Stockholm3

A3P Biomedical’s lead product is Stockholm3, a blood test that combines protein markers, genetic markers and clinical data with a proprietary algorithm in order to detect aggressive prostate cancer at an early stage.